Anti-Neprilysin Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Anti-Neprilysin Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Global Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), By Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,160.01 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Get Your FREE Sample Copy of the Anti-Neprilysin Market Report 2021
Anti-Neprilysin Market – Impact of Coronavirus (Covid-19) Pandemic
Cardiac diseases are one of the leading causes of death worldwide so the demand for anti-neprilysin drugs has slightly reduced but this COVID-19 pandemic has not negatively impacted anti-neprilysin market. There is no reduction in the cases of heart failures, as COVID-19 affects the cardiac system in the end stage of COVID-19 infection. The lockdown policies in different countries have resulted in reduction in the supply of anti-neprilysin drugs, which is expected to affect the patients with cardiac conditions. Many patients with cardiac conditions at home are not able to receive prescribed medications due to the shutdown on transportation.
The increasing number of product approvals and launches, adoption of anti-neprilysin drugs, and distribution agreements among key players are the major factors that are expected to drive growth of the anti-neprilysin market during the forecast period.
The rising adoption of anti-neprilysin drugs is expected to boost growth of the anti-neprilysin market during the forecast period. For instance, in June 2016, an analysis published in JAMA Cardiology found that timely and wide adoption of Entresto (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the U.S. alone. This analysis is based on the results of PARADIGM-HF trails on heart failure statistics, is the first to quantify the possible impact of Entresto’s potential benefit in reducing death.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/4164
Reasons to Purchase this Report
• Current and future of global Anti-Neprilysin market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/4164
Furthermore, the study suggests that delaying routine use of Entresto in clinical practice could have a substantial negative effect on patients, given the expected risk-benefit profile, as it could result in failure to prevent tens of thousands of deaths. These findings demonstrate the significant survival benefits Entresto could offer to those living with HFrEF if patients in the group defined by the authors were given access to treatment.
The launch of new advanced anti-neprilysin drugs in the market is expected to contribute significantly to the anti-neprilysin market growth. For instance, in January 2016, Novartis International AG announced the launch of Entresto (sacubitril/valsartan) in the U.K. Entresto (sacubitril/valsartan) was approved in Europe in November 2015 to treat patients with heart failure and reduced ejection fraction, a condition where the heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body. The drug offers a novel dual mechanism of action to reduce the strain on the failing heart.
Several market players are focused on distribution agreements to expand their product portfolio and gain maximum share in the market. For instance, in November 2016, Laboratorios Farmacéuticos Rovi, S.A. announced that it signed an agreement with Novartis Farmacéutica, S.A. (subsidiary of Novartis in Spain) to market Neparvis (sacubitril/valsartan) in Spain, which corresponds to Entresto of Novartis. Under this marketing agreement, ROVI takes the promotion and distribution rights of Neparvis in the Spain, a medicine indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (the proportion of blood leaving the heart).
Browse 32 Market Data Tables and 34 Figures spread through 168 Pages and in-depth TOC on Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), By Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Forecast to 2027″
To know the latest trends and insights related to global anti-neprilysin market press release
Key Takeaways of the Anti-Neprilysin Market:
- The anti-neprilysin market is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027), owing to the increasing number of product approvals and launches by key players
- Among type, the Sacubitril segment is expected to hold a major revenue share in 2027, owing to increasing R&D activities and product launches, which in turn can increase demand for anti-neprilysin drugs. For instance, in October 2016, in November 2015, Entresto (Sacubitril) was launched in Canada for the treatment of heart failure in patients with New York Heart Association (NYHA) class II or III.
- Major players operating in the global anti-neprilysin market include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Regulatory Scenario
- Reimbursement Scenario
- New Product Launches/Approvals
- Mergers & Acquisitions
- Porter’s Analysis
- PEST Analysis
- Market Dynamics
- Global Anti-Neprilysin Market COVID-19 Impact Analysis
- Pre-COVID Market Analysis
- Post – COVID Market Analysis
- Strategies
- Global Anti-Neprilysin Market, By Drug Type, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Sacubitril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- TD-0714
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- STR-324
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- PL-265
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- LHW-090
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Anti-Neprilysin Market, By Indication, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Acute Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Cancer Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Alzheimer’s Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Anti-Neprilysin Market, By Distribution Channel, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Anti-Neprilysin Market, By Region, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
Major Point Answered in Anti-Neprilysin Market Research Study are: –
• What will the market growth rate, Overview and Analysis by Type of Anti-Neprilysin market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Anti-Neprilysin market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Anti-Neprilysin market?
• Who are Opportunities, Risk and Driving Force of Anti-Neprilysin market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in Anti-Neprilysin market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Anti-Neprilysin market opportunities and threats faced by the vendors in the market?
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837